PAIB-SOs-12
PAIB-SOs-12 is a CYP1A1-activated antimitotic prodrug with affinity for human CYP1A1, with a Ki value of 1.2 μM. PAIB-SOs-12 exhibits nanomolar antiproliferative activity in cancer cells expressing CYP1A1, with a selectivity ratio of over 100 against cancer cells that do not express CYP1A1. PAIB-SOs-12 undergoes CYP1A1-mediated N-dealkylation to form the active metabolite PIB-SO, which induces G2/M cell cycle arrest and microtubule disruption, and shows significantly improved stability in rodent liver microsomes compared to its n-butyl analog. PAIB-SOs-12 can be used in breast cancer-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1422528-30-0
- Formule: C20H22Cl2N2O4S
- Masse moléculaire:457.37
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
CYP1A1 1.2 μM (Ki) |
PAIB-SOs-12 (compound 12) (48 h) potently inhibits the proliferation of MCF7 breast cancer cells expressing CYP1A1, with an IC50 of 50 nM, and exhibits over 100-fold selectivity against CYP1A1-negative HT-29 and M21 cells[1].
PAIB-SOs-12 (65 nM; 48 h) disrupts the microtubule cytoskeleton of MCF7 breast cancer cells expressing CYP1A1[1].
PAIB-SOs-12 (48 h) potently inhibits the proliferation of HT-1080TM A[1] cells expressing CYP1A1, with an IC50 of 30 nM; it exhibits >167-fold and 152-fold selectivity, respectively, compared with CYP1A1-null HT-1080 empty vector cells and wild-type HT-1080 cells[1].
PAIB-SOs-12 (400 nM; 0-60 min) exhibits superior stability in rodent liver, with a half-life of 111 min in mouse liver microsomes (MLMs), 160 min in rat liver microsomes (RLMs), and a sustained half-life of 120 min in human liver microsomes[1].
PAIB-SOs-12 (32-31600 nM; 15 min) exhibits affinity for human CYP1A1, with a competitive inhibition constant (Ki) of 1.2 μM[1].
PAIB-SOs-12 (145 nM; 48 h) induces G2/M cell cycle arrest in MCF7 breast cancer cells expressing CYP1A1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF7 CYP1A1-expressing breast cancer cells
-
Concentration:145 nM
-
Incubation Time:48 h
-
Result:Induced cell cycle arrest in the G2/M phase, with 34% of cells accumulating in this phase, compared to 16% in DMSO-treated control cells.
-
Cell Line:MCF7 CYP1A1-expressing breast cancer cells
-
Concentration:65 nM
-
Incubation Time:48 h
-
Result:Disrupted the microtubule cytoskeleton of MCF7 cells, similar to positive controls CEU-818, CEU-602, and combretastatin A-4.
Chemical Information
-
CAS No. 1422528-30-0
-
Masse moléculaire 457.37
-
Formule C20H22Cl2N2O4S
-
SMILES
O=C1N(CCN1CCCCC)C2=CC=C(S(=O)(OC3=CC(Cl)=CC(Cl)=C3)=O)C=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Chavez Alvarez AC, et al. Homologation of the Alkyl Side Chain of Antimitotic Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonate Prodrugs Selectively Targeting CYP1A1-Expressing Breast Cancers Improves Their Stability in Rodent Liver Microsomes. Journal of medicinal chemistry. 2023 Feb 23;66(4):2477-2497. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PAIB-SOs-12 Related Classifications
HY-187120 Related Classifications
Powered by Bioz